Jim Simons Nrx Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.29 - $0.7 $3,392 - $8,189	-11,700 Reduced 5.84%	188,780 $89,000
Q4 2023 Feb 13, 2024	BUY	$0.26 - $0.47 $9,542 - $17,249	36,700 Added 22.41%	200,480 $92,000
Q3 2023 Nov 14, 2023	BUY	$0.23 - $0.5 $29,964 - $65,140	130,280 Added 388.9%	163,780 $43,000
Q2 2023 Aug 11, 2023	BUY	$0.46 - $0.89 $3,772 - $7,298	8,200 Added 32.41%	33,500 $16,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.4 $5,082 - $10,780	7,700 Added 43.75%	25,300 $17,000
Q4 2022 Feb 13, 2023	BUY	$0.79 - $9.19 $2,492 - $28,994	3,155 Added 21.84%	17,600 $20,000
Q3 2022 Nov 14, 2022	SELL	$0.2 - $8.07 $3,691 - $148,931	-18,455 Reduced 56.09%	14,445 $11,000
Q2 2022 Aug 12, 2022	SELL	$0.51 - $2.42 $54,112 - $256,769	-106,103 Reduced 76.33%	32,900 $20,000
Q1 2022 May 13, 2022	BUY	$2.45 - $5.04 $340,557 - $700,575	139,003 New	139,003 $341,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $110M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.